This week, the Innovative Medicines Initiative (IMI) has launched a new Call for proposals with funding opportunities in cancer, tuberculosis, vaccines, psoriatic arthritis and drugs based on proteins.
IMI will contribute EUR 133 million to the projects funded under the Call; these funds come from Horizon 2020 and will support the participation in the projects of organisations such as universities, small and medium-sized enterprises, and patient groups. EFPIA companies and IMI Associated Partners will contribute EUR 140 million, mostly as ‘in kind’ contributions (e.g. staff time, access to equipment, etc.).
Read more